Migraine Prevention

All commercially insured patients new to Trokendi XR pay nothing for a minimum of 12 prescriptions*—guaranteed.

*Click here for Terms and Conditions.

The World Health Organization considers migraine to be one of the most disabling medical illnesses worldwide1

  • More than 39 million Americans are living with migraine2
  • In the United States, there is an emergency room visit every 10 seconds for headache or migraine3†

Migraine can significantly disrupt time with loved ones, education, and careers1†

In a migraine.com survey of over 4,500 people diagnosed with migraine, respondents revealed that the impact of migraine often goes deeper than health and wellness4:

  • More than half of the respondents reported that they felt embarrassed about having migraine
  • 70 percent reported that they worry about disappointing others

 

There is no evidence that Trokendi XR® (topiramate) reduces these disruptions or emergency room (ER) visits.

 

The average number of days impacted because of headaches in the 3 months prior to the survey4:

  • 7–Missed work or schedule
  • 7–Missed family, social, or leisure activities
  • 5–Productivity at work or school reduced by half or more
  • 3–Productivity in household work reduced by half of more
  • 19.3–Not able to do household work (such as housework, home repairs and maintenance, shopping, caring for children and relatives)

 

The hardest part about living with the migraine is not knowing when it’s gonna happen, and not knowing if…the migraine is gonna ruin your plans.

 

Jamie

Watch Jamie, a real-life Trokendi XR (topiramate) patient, talk about the impact of migraine headache and her experience with Trokendi XR (topiramate).

Individual results may vary.

Preventative therapy is underutilized

  • Studies show that approximately 40% of adult patients with migraine are candidates for preventive therapy5-8
  • However, only about 12% of adults with migraine take preventive medication9

How do acute and preventive treatments differ?

  Acute Preventive
Objective Intended to provide individual symptom relief10 Reduce migraine frequency10
Treatment administration Taken at onset of the attack11 May take several weeks to months of treatment before maximal response is evident12
Additional benefits May be the only treatment needed if the patient has <2 migraines/month11 May help decrease analgesic intake10 May reduce the likelihood of transformation to chronic migraine10,13,14‡

Both acute and preventive therapies may be required.12

In one trial, topiramate did not prevent transformation to chronic migraine.15

Topiramate is prescribed 2.5 times more than any other migraine prevention treatment16

It has been trusted by prescribers and patients alike for over 20 years.17

AAN/AHS guidelines for migraine prevention18§‖¶

AAN/AHS guidelines for migraine prevention

Trokendi XR (topiramate) is the #1 prescribed branded migraine prevention treatment16

Learn how Trokendi XR (topiramate) delivers the efficacy you’d expect with steady, 24-hour migraine prevention16,19

Inclusion of these drugs is based on original guidelines and new evidence not found in the 2012 report.

§Onabotulinum toxin A is FDA approved for the prevention of chronic migraine.
Frovatriptan has a Level A evidence for menstrual migraine.
Level A: ≥2 Class 1 trials; Level B: 1 Class 1 or 2 Class 2 trials.
#USFDA approved for the prevention of migraine.18

Abbreviations: AAN, American Academy of Neurology; AEDs, antiepileptic drugs; AHS, American Headache Society; CI, confidence interval; SSNRI, selective serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS & PRECAUTIONS

DOSING GUIDELINES & CONSIDERATIONS

ADVERSE REACTIONS

 

INDICATION

Please refer to the full Prescribing Information and Medication Guide for additional important information on Trokendi XR.

Trokendi XR (topiramate) extended-release capsules

 

REFERENCES:

  1. Headache disorders. Worldwide Health organization website. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed June 8, 2017.
  2. Migraine Research Foundation. Migraine facts. migraineresearchfoundation.org/about‐migraine/migraine‐facts/. Accessed June 26, 2018.
  3. Migraine Facts. Migraine Research Foundation website. https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed June 8, 2017.
  4. The Real Impact of Migraines on Quality of Life: Data from the 2015 Migraine in America Survey. Migraine.com. https://migraine.com/pro/the-real-impact-of-migraines-on-quality-of-life-data-from-the-2015-migraine-in-america-survey/. Accessed August 2, 2018.
  5. Silberstein SD, Neto W, Schmitt J, et al, for MIGR-001 Study Group. Topiramate in migraine prevention. Arch Neurol. 2004;61:490-495.
  6. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. J Amer Med Assoc. 2004;291:965-973.
  7. Klapper J, on behalf of Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17103-17108.
  8. Matthew NT, Rapoport A, Saper S, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2014;41:119-128.
  9. Lipton RB, Bigal ME, Freitag F, et al, on behalf of AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
  10. Gooriah R, Nimeri R, Ahmed F. Evidence-based treatments for adults with migraine. Pain Res Treat. 2015:629382.
  11. Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008;33(7):404-416.
  12. Silberstein SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973-989.
  13. May A, Schulte AH. Chronic migraine: risk factors, mechanisms, and treatment. Nat Rev Neurol. 2016;12:455-464.
  14. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47:13-21.
  15. Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31:18-30.
  16. Data on File
  17. Silberstein 2005
  18. Silberstein 2012
  19. Trokendi XR package insert